Gujarat Themis Biosyn Limited (NSE:GUJTHEM)

Market Cap	53.37B +19.4%
Revenue (ttm)	1.74B +17.5%
Net Income	486.87M +9.2%
EPS	4.47 +9.1%
Shares Out	n/a
PE Ratio	109.62
Forward PE	n/a
Dividend	0.67 (0.16%)
Ex-Dividend Date	Sep 23, 2026

Volume	74,363
Open	413.40
Previous Close	410.75
Day's Range	409.55 - 422.00
52-Week Range	225.05 - 479.00
Beta	0.51
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 6, 2026

About Gujarat Themis Biosyn

Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals, medicinal chemicals, and active pharmaceutical ingredients in India and internationally. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease; Rifamycin-O, an antibiotic for the treatment of traveller’s diarrhea, irritable bowel syndrome, and hepatic encephalopathy; and Lovastatin. The company was incorporated in 1981...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1981
• Employees: 221
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: GUJTHEM

Financial Performance

In fiscal year 2026, Gujarat Themis Biosyn's revenue was 1.66 billion, an increase of 9.96% compared to the previous year's 1.51 billion. Earnings were 466.82 million, a decrease of -4.29%.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 24, 2026

Data Sources Report a data error